Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 24, 2010. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of executive compensation events rather than a financial performance report.
Material Changes
The material change disclosed is the vesting of share options for Dr. M. M. Slaoui, a Person Discharging Managerial Responsibility. The three-year performance period for a 2007 award under the GlaxoSmithKline Share Option Plan concluded on December 31, 2009. Consequently, the entire original grant of 3,570 American Depositary Shares (ADSs) became exercisable.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The transaction was notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Executive: Dr. M. M. Slaoui (Person Discharging Managerial Responsibility).
- Instrument: 3,570 ADSs under the 2007 Share Option Plan.
- Option Price: US$58.00 per ADS.
- Status: Fully exercisable as of December 31, 2009.
- Notification Date: February 24, 2010.